Eli Chaim Lewis

Title: Eli Chaim Lewis: Innovator in Alpha-1-Antitrypsin Research

Introduction

Eli Chaim Lewis is a prominent inventor based in Beer Sheva, Israel. He has made significant contributions to the field of medical research, particularly in the development of therapies involving alpha-1-antitrypsin proteins. With a total of 7 patents to his name, Lewis continues to push the boundaries of innovation in healthcare.

Latest Patents

Among his latest patents, Lewis has developed mutant alpha-1-antitrypsin compositions and their applications in treating inflammatory diseases. This invention provides novel mutant alpha-1-antitrypsin proteins, pharmaceutical compositions containing these proteins, and methods for their use in treating subjects suffering from inflammatory disorders. Another notable patent focuses on a combined therapy of alpha-1-antitrypsin and temporal T-cell depletion, aimed at preventing graft rejection. This method involves administering a therapeutically effective amount of alpha-1-antitrypsin in conjunction with an anti-CD8 antibody or an antigen-binding fragment thereof.

Career Highlights

Eli Chaim Lewis has worked with esteemed institutions such as the University of Colorado and Ben-Gurion University of the Negev Research and Development Authority. His work in these organizations has allowed him to collaborate with leading experts in the field, further enhancing his research and innovation capabilities.

Collaborations

Lewis has had the opportunity to work alongside notable colleagues, including Charles A. Dinarello and Antonio Abbate. These collaborations have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Eli Chaim Lewis stands out as a significant figure in the realm of medical innovation, particularly in the area of alpha-1-antitrypsin research. His contributions through patents and collaborations continue to impact the field positively.